Novo Nordisk Resubmits Semaglutide 2mg For Type 2 Diabetes In US

by Vandana Singh, Benzinga Editor

May 28, 2021 12:04 PM | 1 min read |

Novo Nordisk A/S NVO has resubmitted a label expansion application to FDA for Ozempic (semaglutide) to introduce a new dose of 2.0 mg.
Semaglutide is a glucagon-like peptide-1 (GLP-1) analog.
The Type 2 diabetes injection is currently approved at 0.5-mg and 1-mg doses given once a week.
The resubmission follows the Refusal to File letter received by the FDA in March.
The agency was looking for additional information about a proposed new manufacturing site. The company said that the already-completed clinical trial program would be sufficient to approve the label expansion application.
The standard review time by the FDA is ten months.
Price Action: NVO shares are up 0.34% at $79.09 during the market session on the last check Friday.

Posted In: Biotech News Health Care FDA General Briefs Diabetes

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.